Kronos Bio is currently advancing two preclinical programs built upon hits identified from the SMM screening platform. In addition, Kronos Bio is pursuing additional discovery efforts against a range of validated, historically challenging targets in oncology.
MYC/Androgen receptor related cofactor (MARC)
Cyclin-dependent kinase 9 (CDK9)
Transcription factors and oncoproteins (multiple)
Novel E3 ligases (multiple)